
|Articles|April 1, 2003
Price Tag Holds Back Biologics for Psoriasis
The use of biologics to treat psoriasis is on the move. A couple of systemic medications have received FDA approval for psoriasis and related conditions, and several more are in the pipeline. Although the drugs are reputed to cause fewer and less serious side effects than traditional psoriasis treatments, that doesn't mean side effects don't exist, and that makes them an issue for some doctors and patients alike.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














